These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36777426)

  • 1. Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis.
    Dubinsky MC; Panaccione R; Lewis JD; Sands BE; Hibi T; Lee SD; Naegeli AN; Shan M; Green LA; Morris N; Arora V; Bleakman AP; Belin R; Travis S
    Crohns Colitis 360; 2022 Jul; 4(3):otac016. PubMed ID: 36777426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
    Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
    Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
    Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
    BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
    Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
    Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
    Long MD; Schreiber S; Hibi T; Gibble TH; Fisher DA; Park G; Moses RE; Higgins PDR; Lindsay JO; Lee SD; Escobar R; Jairath V
    Crohns Colitis 360; 2024 Jan; 6(1):otae001. PubMed ID: 38313767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
    Kobayashi T; Matsuoka K; Watanabe M; Hisamatsu T; Hirai F; Milata J; Li X; Morris N; Arora V; Ishizuka T; Matsuo K; Satoi Y; Milch C; Hibi T
    Intest Res; 2024 Apr; 22(2):172-185. PubMed ID: 38720466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.
    Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
    J Crohns Colitis; 2024 Nov; 18(11):1845-1856. PubMed ID: 38869019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Hunter Gibble T; Abreu MT; Lee S; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Arora V; Panaccione R; Dignass A
    Inflamm Bowel Dis; 2024 Dec; 30(12):2245-2258. PubMed ID: 38459910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Factors Associated With Fecal Urgency Among Patients With Ulcerative Colitis and Crohn's Disease in the Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease.
    Dawwas GK; Jajeh H; Shan M; Naegeli AN; Hunter T; Lewis JD
    Crohns Colitis 360; 2021 Jul; 3(3):otab046. PubMed ID: 36776663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P028 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Patient and Healthcare Professional Perspectives on Experience of Ulcerative Colitis Symptoms.
    Rubin D; Panaccione R; Potts Bleakman A; Kayhan C; Atkinson C; Hunter Gibble T; Ellis H; Healey K; Shan M; Hibi T
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S7. PubMed ID: 37461947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.
    Ghosh S; Sanchez Gonzalez Y; Zhou W; Clark R; Xie W; Louis E; Loftus EV; Panes J; Danese S
    J Crohns Colitis; 2021 Dec; 15(12):2022-2030. PubMed ID: 34107013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
    Armuzzi A; Rubin DT; Schreiber S; Panés J; Fellmann M; Bartolome L; Gruben D; Goetsch M; Bhattacharjee A; Chaparro M; Dubinsky MC
    Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39326009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
    Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V
    Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis.
    Dubinsky MC; Shan M; Delbecque L; Lissoos T; Hunter T; Harding G; Stassek L; Andrae D; Lewis JD
    J Patient Rep Outcomes; 2022 Nov; 6(1):114. PubMed ID: 36334163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
    Hanzel J; Ma C; Jairath V
    Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
    Dubinsky MC; DiBonaventura M; Fan H; Bushmakin AG; Cappelleri JC; Maller E; Thorpe AJ; Salese L; Panés J
    Inflamm Bowel Dis; 2021 Jun; 27(7):983-993. PubMed ID: 32794567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.